• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Life Sciences Investor Forum: Now Available for Online Viewing

    6/13/25 8:35:00 AM ET
    $ATNM
    $BPTH
    $COCH
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNM alert in real time by email

    NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and 12th are now available for online viewing.

    REGISTER AND VIEW PRESENTATIONS

    The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download

    investor materials from the company's resource section.

    Select companies are accepting 1x1 management meeting requests through June 17.

    June 11th





    Presentation
    Ticker(s)
    Nika Pharmaceuticals(OTCQB:NIKA)
    Tivic Health Systems Inc.(NASDAQ:TIVC)
    Adia Nutrition, Inc.(OTCQB:ADIA)
    Sandoz Group AG(OTCQX:SDZNY, SIX: SDZ))



    June 12
    th





    Presentation
    Ticker(s)
    CSL Ltd.(OTCQX:CSLLY, ASX: CSL))
    Sharps Technology, Inc.(NASDAQ:STSS)
    Heidelberg Pharma AG(XETRA: HPHA)
    SBC Medical Group Holdings Incorporated(NASDAQ:SBC)
    Actinium Pharmaceuticals, Inc.(NYSE:ATNM)
    IMUNON, Inc.(NASDAQ:IMNN)
    Bio-Path Holdings, Inc.(OTCQB:BPTH)
    Perimeter Medical Imaging AI, Inc.(OTCQX:PYNKF, TSXV:PINK)
    MetaVia Inc.(NASDAQ:MTVA)
    Conavi Medical Corp.(OTCQB:CNVIF, TSXV:CNVI)
    Vycor Medical, Inc.(OTCQB:VYCO)
    Envoy Medical, Inc.(NASDAQ:COCH)
    Starpharma Holdings Ltd.(OTCQX:SPHRY, ASX: SPL))



    To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    Media Contact:

    OTC Markets Group Inc. +1 (212) 896-4428, [email protected]

    Virtual Investor Conferences Contact:

    John M. Viglotti

    SVP Corporate Services, Investor Access

    OTC Markets Group

    (212) 220-2221

    [email protected]



    Primary Logo

    Get the next $ATNM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ATNM
    $BPTH
    $COCH
    $IMNN

    CompanyDatePrice TargetRatingAnalyst
    MetaVia Inc.
    $MTVA
    12/30/2024$12.00Buy
    H.C. Wainwright
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    8/7/2024$16.00 → $2.00Buy → Neutral
    B. Riley Securities
    Envoy Medical Inc.
    $COCH
    6/24/2024$8.50Buy
    Ascendiant Capital Markets
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    5/14/2024$25.00Overweight
    Stephens
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    9/6/2023$11.60Buy
    HSBC Securities
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    2/21/2023Outperform → Mkt Perform
    William Blair
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    9/8/2022$20.00Overweight
    Cantor Fitzgerald
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    8/25/2022$16.00Buy
    B. Riley Securities
    More analyst ratings

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose

      Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass., July 9, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced dosing of the first patient in the 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity. Top-line data is expected in the fourth quarter of 2025. "T

      7/9/25 8:31:00 AM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tivic Shareholders Approve Key Proposals in Support of Strategic Transformation; Lisa Wolf Appointed Permanent CFO

      Company provides additional management updates Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that key proposals needed to carry out the company's strategic transformation were approved by shareholders at its annual meeting held on June 30, 2025. The approved proposals included the issuance of equity as a form of payment pursuant to Tivic's worldwide exclusive license agreement for Entolimod™ and Entolasta™, including for uses in acute radiation syndrome, neutropenia and other indications in oncology and hematology. Shareholders also approved the Company's issuance of equity in accordance with previously announced financing arrangeme

      7/8/25 8:30:00 AM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Envoy Medical Expands Patent Portfolio with New Issuances in the United States

      White Bear Lake, Minnesota--(Newsfile Corp. - July 8, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of two new patents, further strengthening its intellectual property portfolio in the United States.The U.S. Patent & Trademark Office has issued two additional patents to Envoy Medical:U.S. Patent No. 12,318,607, on June 3, 2025. The title of the patent is Implantable Cochlear System with Integrated Components and Lead Characterization. Aspects of this patent relate to methods of compensating for variability in a middle ear sensor. Input signals from a middl

      7/8/25 8:00:00 AM ET
      $COCH
      Industrial Specialties
      Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Taylor Glen A

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      7/8/25 10:37:33 AM ET
      $COCH
      Industrial Specialties
      Health Care
    • SEC Form 3 filed by new insider Potashnick Robert

      3 - Envoy Medical, Inc. (0001840877) (Issuer)

      7/3/25 2:48:15 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Director Glickman Mark A was granted 28,147 shares, increasing direct ownership by 289% to 37,887 units (SEC Form 4)

      4 - MetaVia Inc. (0001638287) (Issuer)

      7/1/25 4:03:19 PM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Patel Mona Chetan bought $3,675 worth of shares (2,500 units at $1.47), increasing direct ownership by 14% to 20,000 units (SEC Form 4)

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      6/13/25 4:10:30 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Director Patel Mona Chetan bought $14,600 worth of shares (10,000 units at $1.46), increasing direct ownership by 133% to 17,500 units (SEC Form 4)

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      6/10/25 4:11:23 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Chief Financial Officer Woodworth Marshall H bought $9,940 worth of shares (14,200 units at $0.70), increasing direct ownership by 47% to 44,279 units (SEC Form 4)

      4 - MetaVia Inc. (0001638287) (Issuer)

      6/4/25 4:01:12 PM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on MetaVia with a new price target

      H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00

      12/30/24 7:25:48 AM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinum Pharma downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded Actinum Pharma from Buy to Neutral and set a new price target of $2.00 from $16.00 previously

      8/7/24 12:40:34 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ascendiant Capital Markets initiated coverage on Envoy Medical with a new price target

      Ascendiant Capital Markets initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $8.50

      6/24/24 7:29:10 AM ET
      $COCH
      Industrial Specialties
      Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    SEC Filings

    See more
    • Imunon Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Imunon, Inc. (0000749647) (Filer)

      7/11/25 5:00:47 PM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by MetaVia Inc.

      EFFECT - MetaVia Inc. (0001638287) (Filer)

      7/11/25 12:15:12 AM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by MetaVia Inc.

      424B3 - MetaVia Inc. (0001638287) (Filer)

      7/10/25 5:05:34 PM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Leadership Updates

    Live Leadership Updates

    See more
    • SBC Medical Appoints New Chief Marketing Officer to Enhance Marketing Infrastructure and Strengthen Brand Power

      IRVINE, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (NASDAQ:SBC) ("SBC Medical"), a global franchise and provider of services for aesthetic clinics, is pleased to announce the appointment of Shinya Inoue as Chief Marketing Officer (CMO), effective July 1, 2025. As CMO of SBC Medical, Mr. Inoue will lead efforts to enhance the brand value of the group's portfolio, including Shonan Beauty Clinic, one of Japan's largest aesthetic medical brands. He will also spearhead the evolution and optimization of the company's marketing infrastructure with a strong focus on digital innovation. Through strategic initiatives that address the increasing diversity of

      7/1/25 8:00:00 AM ET
      $SBC
      Medical/Nursing Services
      Health Care
    • Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team

      Handley Joins as President of Tivic Biopharma and Chief Operating Officer of Tivic Health Following Its Licensing of Strategic Biopharma Assets From Statera Biopharma Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today that Michael K. Handley, formerly Chief Executive Officer, President and Chairman of Statera Biopharma, Inc., has joined Tivic Health as the President of Tivic Biopharma, a newly formed division of Tivic Health. Additionally, he will assume the role of Chief Operating Officer of Tivic Health and will work closely with the CEO and other leadership team members to develop and operationalize company-wide strategies. His key responsi

      2/24/25 8:15:00 AM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer

      Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology and immunology LAWRENCEVILLE, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the appointment of Douglas V. Faller, M.D., Ph.D., as chief medical officer, effective February 18, 2025. In this role, Dr. Faller will lead the company's clinical strategy including advancing its lead program IMNN-001 for the treatment of newly diagnosed advanced ovarian cancer, which is on track to enter a Phase 3 pivotal trial in the first quarter of 202

      2/10/25 8:05:00 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Imunon Inc.

      SC 13G - Imunon, Inc. (0000749647) (Subject)

      11/14/24 5:37:34 PM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Imunon Inc.

      SC 13G/A - Imunon, Inc. (0000749647) (Subject)

      11/14/24 12:17:50 PM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Envoy Medical Inc.

      SC 13G - Envoy Medical, Inc. (0001840877) (Subject)

      11/14/24 8:49:34 AM ET
      $COCH
      Industrial Specialties
      Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Financials

    Live finance-specific insights

    See more
    • Bio-Path Holdings Provides Clinical and Operational Update

      HOUSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced highlights from the recent clinical development and operational update conference call and webcast held May 26, 2025. An archived webcast of the event can be accessed here. "Our business model centers around generating new drug candidates from our DNAbilize® platform and licensing them for final development and commercialization with partners that have expertise and scale to successfully bring them to market," sa

      6/3/25 7:00:00 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025

      HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced that it will host a live conference call and audio webcast on Thursday, May 29, 2025 at 8:30 a.m. ET to provide a comprehensive business overview. To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company's website, www.biopathho

      5/22/25 4:30:00 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tivic Reports First Quarter 2025 Financial Results and Provides Updates on Business Transformation

      Pre-recorded Conference Call to Follow at 1:30 p.m. PDT/4:30 p.m. EDT Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced financial results for the first quarter ended March 31, 2025 and outlined operational highlights based on its newly expanded clinical pipeline. "This is a defining time for the company. During the quarter we initiated a significant strategic shift, dramatically expanding Tivic's clinical pipeline for restoring immune system health," stated Tivic CEO Jennifer Ernst. "In February, we executed a comprehensive worldwide exclusive licensing agreement for the Phase III TLR5 agonist, Entolimod and its molecular derivative, Ent

      5/15/25 4:05:00 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care